Program
peginterferon alfa-2a
Also written as “peginterferon alfa-2a [Pegasys]”, “Peginterferon alfa-2a” and “Pegylated Interferon Alfa-2a”.
Its studies are mostly in Hepatitis C, Chronic · Hepatitis B, Chronic · Hepatitis C · Hepatitis D, Chronic · Leukemia, Myelogenous, Chronic, BCR-ABL Positive, led by 6 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 670 open or running | phase 4since Feb 10, 2004 | Nov 12, 2002 | none ahead |
| Vertex Pharmaceuticals | 80 open or running | phase 4since Nov 3, 2011 | Jul 27, 2004 | none ahead |
| Johnson & Johnson | 50 open or running | phase 3since Dec 6, 2011 | Dec 6, 2011 | none ahead |
| getz-pharma | 10 open or running | phase 4since Nov 2, 2015 | Nov 2, 2015 | none ahead |
| janssen-infectious-diseases-bvba | 10 open or running | phase 3since Oct 28, 2010 | Oct 28, 2010 | none ahead |
| Nanogen Pharmaceutical Biotechnology Joint Stock | 10 open or running | phase 4since Apr 3, 2025 | Apr 3, 2025 | none ahead |
Also a collaborator on its studies: Dimension Research, CPR Pharma Services Pty Ltd, Australia, Roche Pharma, ViroChem Pharma and Tibotec Pharmaceutical.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 43 studies since May 16, 2007.
- Oct 8, 2015Phase 1 study in Healthy VolunteersHoffmann-La Roche · NCT02573025 · 277 enrolled · Australia, Hong Kong, New Zealand and more
- Oct 14, 2015Phase 2 study in Carcinoma, HepatocellularHoffmann-La Roche · NCT02576964 · 16 enrolled · China, Taiwan, Thailand
- Nov 2, 2015getz-pharma’s first study: phase 4 study in Hepatitis CNew to getz-pharmagetz-pharma · NCT02601976 · 64 enrolled
- Nov 4, 20152 phase 4 studies in Hepatitis B, ChronicHoffmann-La Roche · NCT02604823, NCT02598063
- Dec 11, 2015Phase 4 study in Hepatitis C, ChronicHoffmann-La Roche · NCT02641379 · 737 enrolled · Austria
- Mar 18, 2016Phase 2 study in Hepatitis C, ChronicHoffmann-La Roche · NCT02716779 · 68 enrolled · Germany
- Apr 1, 2016Phase 2 study in Hepatitis D, ChronicHoffmann-La Roche · NCT02731131 · 12 enrolled · Italy
- Apr 5, 20162 phase 3 studiesHoffmann-La Roche · NCT02732639, NCT02736721
- May 3, 20162 phase 3 studiesHoffmann-La Roche · NCT02762383, NCT02791256
- May 31, 2016Phase 4 study in Hepatitis B, ChronicHoffmann-La Roche · NCT02791269 · 24 enrolled · New Zealand
- Jun 16, 2016Phase 3 study in Hepatitis C, ChronicHoffmann-La Roche · NCT02806505 · 81 enrolled · Austria, Brazil, France and more
- Jul 6, 2016Phase 3 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveHoffmann-La Roche · NCT02829775 · 9 enrolled · Bulgaria, Canada, India and more
- Aug 9, 2016Phase 4 study in Hepatitis C, ChronicHoffmann-La Roche · NCT02864199 · 63 enrolled · United States, Brazil, France and more
- Apr 3, 2025Nanogen Pharmaceutical Biotechnology Joint Stock’s first study: phase 4 study in Hepatitis C, ChronicNew to Nanogen Pharmaceutical Biotechnology Joint StockNanogen Pharmaceutical Biotechnology Joint Stock · NCT06922643 · 100 enrolled
TargetBeta
“Interferon alpha/beta receptor agonist”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Interferon beta-1arule | Biogen | phase 4 | 60 |
| peginterferon alfa-2brule | Merck | phase 4 | 56 |
Studies
The newest 60 of 83 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06922643Hepatitis C, Chronic | 4 | Completed | Nanogen Pharmaceutical Biotechnology Joint Stock | Jan 21, 2013 | 100 |
| NCT02864199Hepatitis C, Chronic · United States, Brazil, France and more | 4 | Completed | Hoffmann-La Roche | Sep 2007 | 63 |
| NCT02829775Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Bulgaria, Canada, India and more | 3 | Completed | Hoffmann-La Roche | Jan 2008 | 9 |
| NCT02806505Hepatitis C, Chronic · Austria, Brazil, France and more | 3 | Completed | Hoffmann-La Roche | Aug 2007 | 81 |
| NCT02791269Hepatitis B, Chronic · New Zealand | 4 | Completed | Hoffmann-La Roche | Jul 2008 | 24 |
| NCT02791256Hepatitis C, Chronic · Belgium | 3 | Terminated | Hoffmann-La Roche | Jun 2008 | 23 |
| NCT02762383HIV/HCV Coinfection · Belgium | 3 | Terminated | Hoffmann-La Roche | Jun 2009 | 19 |
| NCT02736721Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Germany | 3 | Completed | Hoffmann-La Roche | Nov 2010 | 41 |
| NCT02732639Hepatitis D, Chronic · Romania | 3 | Completed | Hoffmann-La Roche | Dec 2008 | 31 |
| NCT02731131Hepatitis D, Chronic · Italy | 2 | Completed | Hoffmann-La Roche | May 2009 | 12 |
| NCT02716779Hepatitis C, Chronic · Germany | 2 | Completed | Hoffmann-La Roche | Apr 2010 | 68 |
| NCT02641379Hepatitis C, Chronic · Austria | 4 | Completed | Hoffmann-La Roche | Nov 2013 | 737 |
| NCT02604823Hepatitis B, Chronic · China | 4 | Completed | Hoffmann-La Roche | Nov 2005 | 307 |
| NCT02598063Hepatitis B, Chronic · China, Hong Kong | 4 | Completed | Hoffmann-La Roche | Apr 2009 | 255 |
| NCT02601976Hepatitis C | 4 | Completed | getz-pharma | Sep 2012 | 64 |
| NCT02576964Carcinoma, Hepatocellular · China, Taiwan, Thailand | 2 | Completed | Hoffmann-La Roche | Nov 2008 | 16 |
| NCT02573025Healthy Volunteers · Australia, Hong Kong, New Zealand and more | 1 | Completed | Hoffmann-La Roche | Apr 11, 2016 | 277 |
| NCT02570191Hepatitis B, Chronic · Bulgaria | 4 | Completed | Hoffmann-La Roche | Feb 2007 | 60 |
| NCT02401737Hepatitis B, Chronic · United States, China, Korea, Republic of and more | 1 | Completed | Johnson & Johnson | May 18, 2016 | 58 |
| NCT02263079Pediatric Immuno-Tolerant Chronic Hepatitis B · United States, Australia, Belgium and more | 3 | Completed | Hoffmann-La Roche | Jan 29, 2020 | 62 |
| NCT02112799Hepatitis B, Chronic · New Zealand | 1 | Completed | Johnson & Johnson | May 18, 2016 | 55 |
| NCT01853254Hepatitis C, Chronic · United States, Australia, Brazil and more | 3 | Completed | Hoffmann-La Roche | Sep 2011 | 272 |
| NCT01787279Hepatitis B, Chronic · Morocco | 4 | Completed | Hoffmann-La Roche | May 2009 | 59 |
| NCT01749150Hepatitis C, Chronic · Korea, Republic of, Taiwan, Thailand | 2 | Completed | Hoffmann-La Roche | Feb 2015 | 61 |
| NCT01706575Hepatitis B, Chronic · Italy | 2 | Completed | Hoffmann-La Roche | Sep 2013 | 76 |
| NCT01591460Hepatitis C, Chronic · Austria, Germany, Hungary and more | 4 | Completed | Hoffmann-La Roche | Jun 2014 | 165 |
| NCT01585324Hepatitis C, Chronic · Czech Republic | 4 | Completed | Hoffmann-La Roche | Jan 2014 | 30 |
| NCT01513941Hepatitis C, Chronic · Australia, Brazil, France and more | 3 | Completed | Johnson & Johnson | Mar 2014 | 163 |
| NCT01519921Hepatitis B, Chronic · Korea, Republic of | 4 | Completed | Hoffmann-La Roche | Jun 2008 | 150 |
| NCT01571583Hepatitis C, Chronic · Austria, Belgium, France and more | 3 | Completed | Johnson & Johnson | Apr 2014 | 74 |
| NCT01519960Hepatitis B, Chronic · United States, Australia, Belgium and more | 3 | Completed | Hoffmann-La Roche | Jul 9, 2015 | 165 |
| NCT01498068Hepatitis C · Russian Federation | 3 | Completed | Johnson & Johnson | Apr 2012 | 36 |
| NCT01467505Hepatitis C · United States, Canada | 2 | Terminated | Vertex Pharmaceuticals | Apr 2014 | 61 |
| NCT01467492Hepatitis C · United States | 4 | Terminated | Vertex Pharmaceuticals | May 2014 | 121 |
| NCT01467479Hepatitis C · United States, Canada, Germany and more | 3 | Terminated | Vertex Pharmaceuticals | Feb 2014 | 185 |
| NCT01459913Hepatitis C, Chronic · United States, Austria, Canada and more | 3 | Terminated | Vertex Pharmaceuticals | Jan 2014 | 239 |
| NCT01447420Hepatitis C, Chronic · Brazil | 4 | Completed | Hoffmann-La Roche | Nov 2012 | 129 |
| NCT01429792Hepatitis C, Chronic · Israel | 4 | Completed | Hoffmann-La Roche | Jun 10, 2013 | 1,013 |
| NCT01337375Hepatitis C, Chronic · Germany | 1 | Completed | Hoffmann-La Roche | Apr 2012 | 31 |
| NCT01278134Hepatitis C, Chronic · United States, France, Germany and more | 2 | Completed | Hoffmann-La Roche | Oct 2012 | 170 |
| NCT01296971Hepatitis C, Chronic | 3 | Withdrawn | Hoffmann-La Roche | Dec 2009 | 0 |
| NCT01258101Hepatitis C, Chronic · Austria | 4 | Completed | Hoffmann-La Roche | Jul 2008 | 395 |
| NCT01237496Hepatitis B, Chronic · Italy | 3 | Completed | Hoffmann-La Roche | Sep 2009 | 17 |
| NCT01241760Hepatitis C · United States, Australia, Austria and more | 3 | Completed | janssen-infectious-diseases-bvba | Aug 2012 | 744 |
| NCT01095835Hepatitis B, Chronic · Italy | 3 | Completed | Hoffmann-La Roche | Jan 2010 | 131 |
| NCT01086085Hepatitis B, Chronic · China | 4 | Completed | Hoffmann-La Roche | Mar 2013 | 265 |
| NCT01033448Hepatitis C, Chronic · Israel | 4 | Completed | Hoffmann-La Roche | Jun 2013 | 59 |
| NCT00983853Hepatitis C · United States, France, Germany and more | 2 | Completed | Vertex Pharmaceuticals | Mar 2012 | 62 |
| NCT00962975Hepatitis B, Chronic · United States, New Zealand, Singapore and more | 1 | Completed | Hoffmann-La Roche | May 2013 | 29 |
| NCT00962871Hepatitis B, Chronic · United States, New Zealand, Singapore and more | 1 | Completed | Hoffmann-La Roche | Feb 2012 | 30 |
| NCT00940485Hepatitis B, Chronic · China | 4 | Completed | Hoffmann-La Roche | Dec 2011 | 200 |
| NCT00927082Hepatitis B, Chronic · Australia, Brazil, China and more | 4 | Completed | Hoffmann-La Roche | Nov 2014 | 383 |
| NCT00922779Hepatitis C, Chronic · Russian Federation | 4 | Completed | Hoffmann-La Roche | Jun 2012 | 6,661 |
| NCT00911963Hepatitis C · United States, Argentina, Canada and more | 2 | Completed | Vertex Pharmaceuticals | Sep 2012 | 49 |
| NCT00800748Hepatitis C, Chronic · Czechia, Slovakia | 4 | Completed | Hoffmann-La Roche | Jan 9, 2009 | 372 |
| NCT00800735Hepatitis C, Chronic · United States, Austria, Canada and more | 3 | Completed | Hoffmann-La Roche | Mar 2012 | 30 |
| NCT00623428Hepatitis C, Chronic · United States, Australia, Austria and more | 3 | Completed | Hoffmann-La Roche | May 2012 | 235 |
| NCT00487747Hepatitis B, Chronic · Russian Federation | 4 | Completed | Hoffmann-La Roche | Oct 2009 | 18 |
| NCT00483938Hepatitis C, Chronic · United States, Canada | 3 | Completed | Hoffmann-La Roche | May 2010 | 236 |
| NCT00475072Hepatitis C, Chronic · Mexico | 4 | Completed | Hoffmann-La Roche | Jul 2006 | 14 |
How it is read
Names in the registry
- “peginterferon alfa-2a [Pegasys]”, 38 entries
- “Peginterferon alfa-2a”, 21 entries
- “peginterferon alfa-2a”, 9 entries
- “Pegylated Interferon Alfa-2a”, 5 entries
- “peginterferon alfa-2a [PEGASYS]”, 3 entries
Conditions, from the studies’ own filings
- Hepatitis C, Chronic, 43 studies
- Hepatitis B, Chronic, 28 studies
- Hepatitis C, 17 studies
- Hepatitis D, Chronic, 3 studies
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.